Searching On:

Disease:

Gene:

ERBB2 (HER2), Overexpression

View:
Expand Collapse No disease selected  - General Description
Mass General Hospital Cancer Center treats patients with many cancer types. To learn more about the different cancer types that can be treated at the Cancer Center, please visit the Cancer Center website at the following page: http://www.massgeneral.org/cancer/services/
Expand Collapse ERBB2 (HER2)  - General Description ERBB2, often called HER2, is a gene that provides the code for making a cell surface growth receptor called the ERBB2 (HER2). When certain growth factors (proteins that stimulate cell growth and division) bind to this receptor, they activate a signaling system inside the cell that ultimately promotes diverse functions such as growth, interaction and adhesion between cells, and ability of the cell to migrate within tissues. In some tumors, the activation of HER2 signaling is an important mechanism that drives the disease process. This can occur through HER2 gene amplification (the most common mechanism) or HER2 gene mutation in cancer cells. Extra copies of the ERBB2 (HER2) gene (gene amplification) have been found in a number of different cancers. This causes the cancer cells to make excess HER2 (overexpression), which in turn, tells the cells to grow and divide in an uncontrolled manner. Genetic mutations (changes in the DNA sequence that codes the ERBB2 (HER2) protein have also been found in certain tumors. Source: Genetics Home ReferenceERBB2, often called HER2, is a gene that provides the code for making a cell surface growth receptor called the ERBB2 (HER2). When certain growth factors (proteins that stimulate cell growth and division) bind to this receptor, they activate a signaling system inside the cell that ultimately promotes diverse functions such as growth, interaction and adhesion between cells, and ability of the cell to migrate within tissues. In some tumors, the activation of HER2 signaling is an important mechanism that drives the disease process. This can occur through HER2 gene amplification (the most common mechanism) or HER2 gene mutation in cancer cells. Extra copies of the ERBB2 (HER2) gene (gene amplification) have been found in a number of different cancers. This causes the cancer cells to make excess HER2 (overexpression), which in turn, tells the cells to grow and divide in an uncontrolled manner. Genetic mutations (changes in the DNA sequence that codes the ERBB2 (HER2) protein have also been found in certain tumors. Source: Genetics Home Reference
CLICK IMAGE FOR MORE INFORMATION
ERBB2, often called HER2, is a gene that provides the code for making a cell surface growth receptor called the ERBB2 (HER2). When certain growth factors (proteins that stimulate cell growth and division) bind to this receptor, they activate a signaling system inside the cell that ultimately promotes diverse functions such as growth, interaction and adhesion between cells, and ability of the cell to migrate within tissues. In some tumors, the activation of HER2 signaling is an important mechanism that drives the disease process. This can occur through HER2 gene amplification (the most common mechanism) or HER2 gene mutation in cancer cells.

Extra copies of the ERBB2 (HER2) gene (gene amplification) have been found in a number of different cancers. This causes the cancer cells to make excess HER2 (overexpression), which in turn, tells the cells to grow and divide in an uncontrolled manner. Genetic mutations (changes in the DNA sequence that codes the ERBB2 (HER2) protein have also been found in certain tumors.

Source: Genetics Home Reference
ERBB2, often called HER2, is a gene that provides the code for making a cell surface growth receptor called the ERBB2 (HER2). When certain growth factors (proteins that stimulate cell growth and division) bind to this receptor, they activate a signaling system inside the cell that ultimately promotes diverse functions such as growth, interaction and adhesion between cells, and ability of the cell to migrate within tissues. In some tumors, the activation of HER2 signaling is an important mechanism that drives the disease process. This can occur through HER2 gene amplification (the most common mechanism) or HER2 gene mutation in cancer cells.

Extra copies of the ERBB2 (HER2) gene (gene amplification) have been found in a number of different cancers. This causes the cancer cells to make excess HER2 (overexpression), which in turn, tells the cells to grow and divide in an uncontrolled manner. Genetic mutations (changes in the DNA sequence that codes the ERBB2 (HER2) protein have also been found in certain tumors.

Source: Genetics Home Reference
PubMed ID's
15864276, 9130710, 15457249, 16397024, 18772890, 16843263, 16988931, 22899400
Expand Collapse Overexpression  in ERBB2 (HER2)
In some tumors, ERBB2 (Her2/EGFR) has been found to be expressed at a much higher level than in normal cells. This is called overexpression. The overexpression of a gene results in a much higher level of the ERBB2 (HER2/EGFR) protein in cancer cells, which drives tumor cell growth. Testing for overexpression of ERBB2/HER2/EGFR (all names for the same gene) is performed at MGH. Treatment and clinical trials for ERBB2 overexpression are underway at MGH and other large academic centers.
In some tumors, ERBB2 (Her2/EGFR) has been found to be expressed at a much higher level than in normal cells. This is called overexpression. The overexpression of a gene results in a much higher level of the ERBB2 (HER2/EGFR) protein in cancer cells, which drives tumor cell growth. Testing for overexpression of ERBB2/HER2/EGFR (all names for the same gene) is performed at MGH. Treatment and clinical trials for ERBB2 overexpression are underway at MGH and other large academic centers.

Share with your Physican

Print information for your Physician.

Print information

Your Matched Clinical Trials

Trial Matches: (G) - Gene, (M) - Mutation
Trial Status: Showing Results: 1-10 of 12 Per Page:
12Next »
Protocol # Title Location Status Match
NCT02491099 A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma MGH Open G
NCT02716116 A Trial of TAK-788 (AP32788) in Non-small Cell Lung Cancer (NSCLC) A Trial of TAK-788 (AP32788) in Non-small Cell Lung Cancer (NSCLC) MGH Open G
NCT03587740 ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer MGH Open G
NCT03716180 DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC MGH Open G
NCT01494662 HKI-272 for HER2-Positive Breast Cancer and Brain Metastases HKI-272 for HER2-Positive Breast Cancer and Brain Metastases MGH Open G
NCT01953926 Neratinib HER Mutation Basket Study (SUMMIT) Neratinib HER Mutation Basket Study (SUMMIT) MGH Open G
NCT03095352 Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease MGH Open G
NCT03318939 Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation MGH Open G
NCT02500199 Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors MGH Open G
NCT01872975 Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery MGH Open G
Trial Status: Showing Results: 1-10 of 12 Per Page:
12Next »

Share with your Physican

Print information for your Physician.

Print information